AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for approval of a combination therapy for lung cancer developed in partnership with HUTCHMED. The application centers on a drug pairing intended to treat patients with advanced or metastatic non-small cell lung cancer. This filing builds upon positive clinical trial data showcasing the combination’s efficacy. The potential approval would expand treatment options within the United States for this challenging disease. AstraZeneca anticipates a decision from the FDA within the standard review timeframe. The collaboration with HUTCHMED represents a significant effort for AstraZeneca to broaden its oncology portfolio. This move underscores the pharmaceutical giant’s ongoing commitment to addressing unmet needs in cancer care within the United States.